{
  "docId": "019dd923-622c-750b-8b97-5cb48bf2a635",
  "docSlug": "b8afd3741673",
  "documentTitle": "Chinook Therapeutics Inc (KDNY)",
  "authorId": "51_Muddy_Waters",
  "authorName": "Carson C. Block",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-05-16 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77272725,
  "pageNumber": 23,
  "pageCount": 36,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "preempt_rebuttal",
  "function": "preempt_rebuttal",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "Includes a table detailing orphan drug designation and marketing approval for Filspari (sparsentan).",
  "elementsJson": [
    "paragraph",
    "data_table",
    "footnote"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b97-5cb48bf2a635/23",
  "deckHref": "/decks/019dd923-622c-750b-8b97-5cb48bf2a635",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b97-5cb48bf2a635.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b97-5cb48bf2a635#slide-23",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "If side effects had occurred at the same rate that they did in the SONAR study, there should have been heart failures associated with fluid retention; the fact that we do not makes for an astonishing contrast in safety.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-25b7-709e-b8d1-959db999521d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.78,
        "x": 0.11,
        "y": 0.56
      },
      "kind": "paragraph",
      "text": "Sparsentan appears to have a lower risk profile than atrasentan for key complications in chronic kidney disease. In the PROTECT study, a clinical population of ~200 patients who were administered sparsentan suffered no cases of heart failure.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1dc17a03-012b-4e44-8292-714be350f188",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.78,
        "x": 0.11,
        "y": 0.69
      },
      "kind": "paragraph",
      "text": "The smaller DUET study of sparsentan, similarly, displayed a much less alarming pattern of severe adverse effects than we saw in SONAR. There were, again, no reported cases of heart failure; anemia was also much better controlled.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b15df5f8-4c6a-483c-a5ef-fca68e47ed8b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.78,
        "x": 0.11,
        "y": 0.09
      },
      "kind": "paragraph",
      "text": "PROTECT study of sparsentan showed no hepatic toxicity issues. One expert involved in the SONAR study told us that the hepatic toxicity warning was likely only required of sparsentan because of its membership in the ERA drug class.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ec48f44c-c976-4e69-a5e0-66d36c915326",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.78,
        "x": 0.11,
        "y": 0.84
      },
      "kind": "source-note",
      "text": "120-124: References to Lancet articles, expert calls, and clinicaltrials.gov data.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f265826e-3513-4397-801e-58c7008c2eec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.28,
        "w": 0.75,
        "x": 0.13,
        "y": 0.18
      },
      "kind": "table",
      "text": "Generic Name: sparsentan; Trade Name: Filspari; Date Designated: 01/11/2021; Sponsor: Travere Therapeutics, Inc.; Marketing Approval Date: 02/17/2023; Approved Labeled Indication: to reduce proteinuria in adults with primary IgAN...",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2cbd2c99-f919-42d6-8172-b489b93fec53",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "preempt_rebuttal",
      "slug": null,
      "matchId": "a37c0c07-ea41-4e47-b2ee-d94492f77e62",
      "evidence": "The slide explicitly addresses potential concerns about hepatic toxicity and heart failure by comparing study results to preempt negative assumptions.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}